Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

Leerink Partners analyst Marc Goodman maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and ...

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...

Gifting allows recipients to access the article for free. The hair-care company Johnson Products is justly celebrated as the first Black-owned company to go public, leading to a listing on the ...